Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Sarah Milgrom

Concepts (363)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease
41
2026
171
11.960
 Why?
Radiotherapy, Intensity-Modulated
17
2026
142
4.110
 Why?
Positron Emission Tomography Computed Tomography
17
2026
117
3.810
 Why?
Tumor Burden
7
2026
322
2.330
 Why?
Fluorodeoxyglucose F18
8
2026
162
2.330
 Why?
Radiotherapy
14
2025
206
2.200
 Why?
Lymphoma
10
2025
233
2.090
 Why?
Radiotherapy Planning, Computer-Assisted
15
2026
149
2.070
 Why?
Antineoplastic Combined Chemotherapy Protocols
33
2026
1958
2.050
 Why?
Whole-Body Irradiation
3
2026
76
1.910
 Why?
Radiation Injuries
9
2025
151
1.890
 Why?
Radiotherapy Dosage
18
2026
289
1.710
 Why?
Central Nervous System Neoplasms
9
2021
174
1.700
 Why?
Radiopharmaceuticals
6
2023
207
1.600
 Why?
Hematologic Neoplasms
2
2026
162
1.560
 Why?
Lymphoma, Non-Hodgkin
6
2024
124
1.450
 Why?
Neoplasm Staging
31
2026
1465
1.410
 Why?
Lymphoma, Large B-Cell, Diffuse
8
2024
192
1.270
 Why?
Sarcoma
2
2023
205
1.190
 Why?
Neoplasm Recurrence, Local
13
2023
1141
1.180
 Why?
Salvage Therapy
11
2024
162
1.180
 Why?
Mediastinal Neoplasms
5
2021
51
1.090
 Why?
Endometrial Neoplasms
4
2014
208
1.080
 Why?
Neoplasms
7
2026
2884
1.060
 Why?
Prognosis
24
2026
4293
1.060
 Why?
Hematopoietic Stem Cell Transplantation
7
2024
676
1.040
 Why?
Combined Modality Therapy
22
2024
1268
1.040
 Why?
Radiotherapy, Adjuvant
7
2024
222
0.970
 Why?
Humans
122
2026
144957
0.940
 Why?
Positron-Emission Tomography
9
2025
343
0.930
 Why?
Neoplasms, Radiation-Induced
2
2026
99
0.930
 Why?
Rhabdomyosarcoma
2
2024
64
0.930
 Why?
Neoplasms, Second Primary
2
2026
100
0.900
 Why?
Sarcoma, Ewing
2
2024
103
0.890
 Why?
Proton Therapy
2
2026
15
0.870
 Why?
Disease Progression
7
2024
2852
0.840
 Why?
Clinical Trials as Topic
2
2026
1054
0.800
 Why?
Radiation
2
2020
24
0.800
 Why?
Child
28
2026
22657
0.790
 Why?
Craniopharyngioma
1
2024
77
0.790
 Why?
Young Adult
36
2026
14126
0.790
 Why?
Radiation Exposure
1
2023
63
0.760
 Why?
Pituitary Neoplasms
1
2024
190
0.740
 Why?
Adenocarcinoma
3
2014
931
0.730
 Why?
Lymphoma, Follicular
5
2020
56
0.730
 Why?
Salivary Glands
2
2021
36
0.720
 Why?
Smiling
1
2021
6
0.710
 Why?
Adolescent
33
2026
22453
0.700
 Why?
Xerostomia
1
2021
13
0.690
 Why?
Retrospective Studies
39
2026
17101
0.680
 Why?
Tooth Abnormalities
1
2021
16
0.680
 Why?
Brachytherapy
1
2021
134
0.650
 Why?
Face
1
2021
174
0.630
 Why?
Cancer Survivors
2
2026
327
0.630
 Why?
Chemoradiotherapy
9
2021
239
0.630
 Why?
Doxorubicin
13
2025
397
0.620
 Why?
Bleomycin
9
2025
253
0.620
 Why?
Aged, 80 and over
23
2026
8279
0.610
 Why?
Vinblastine
9
2025
75
0.610
 Why?
Intraocular Lymphoma
2
2016
3
0.600
 Why?
Dacarbazine
9
2025
100
0.600
 Why?
Aged
43
2026
25947
0.590
 Why?
Adult
54
2026
40506
0.590
 Why?
Infertility, Female
2
2025
112
0.580
 Why?
Middle Aged
51
2026
35928
0.570
 Why?
Lymphoma, B-Cell, Marginal Zone
4
2019
19
0.570
 Why?
Organs at Risk
4
2026
37
0.570
 Why?
Rectal Neoplasms
3
2016
158
0.560
 Why?
Female
63
2026
78376
0.540
 Why?
Radiotherapy, Image-Guided
4
2026
39
0.540
 Why?
Cerebellar Neoplasms
1
2020
177
0.540
 Why?
Breast Neoplasms
6
2026
2456
0.530
 Why?
Medulloblastoma
1
2020
215
0.530
 Why?
Recurrence
9
2020
1135
0.510
 Why?
Meningeal Neoplasms
1
2018
94
0.500
 Why?
Leukemia, Biphenotypic, Acute
1
2016
4
0.500
 Why?
Male
55
2026
72406
0.490
 Why?
Leukemia, Myeloid, Acute
2
2023
683
0.490
 Why?
Patient Satisfaction
1
2020
705
0.470
 Why?
Head and Neck Neoplasms
1
2021
562
0.470
 Why?
Graft vs Host Disease
2
2024
264
0.460
 Why?
Treatment Outcome
26
2026
11695
0.460
 Why?
Mediastinum
4
2026
23
0.450
 Why?
Eye Diseases
1
2016
94
0.440
 Why?
Brain Neoplasms
3
2023
1322
0.440
 Why?
Follow-Up Studies
16
2025
5417
0.430
 Why?
Survival Rate
12
2021
2092
0.420
 Why?
Disease-Free Survival
12
2020
769
0.410
 Why?
Glycolysis
3
2023
340
0.400
 Why?
Endometrium
1
2013
61
0.390
 Why?
Peritoneal Cavity
1
2013
30
0.390
 Why?
Digestive System Surgical Procedures
1
2014
110
0.380
 Why?
Palate, Hard
1
2012
5
0.380
 Why?
Lymphoma, B-Cell
3
2021
132
0.380
 Why?
Stomach Neoplasms
3
2019
128
0.370
 Why?
Chemoradiotherapy, Adjuvant
3
2019
44
0.370
 Why?
Mastectomy, Simple
1
2012
1
0.370
 Why?
Image Enhancement
1
2013
199
0.360
 Why?
Neoadjuvant Therapy
2
2016
463
0.350
 Why?
Sentinel Lymph Node Biopsy
1
2012
118
0.350
 Why?
Carcinoma, Lobular
1
2012
56
0.350
 Why?
Carcinoma, Ductal, Breast
1
2012
88
0.350
 Why?
Child, Preschool
8
2026
11799
0.330
 Why?
Adrenal Gland Neoplasms
1
2012
101
0.330
 Why?
Radiotherapy, Conformal
2
2026
74
0.320
 Why?
Biopsy
6
2020
1077
0.310
 Why?
Disease Management
6
2019
647
0.310
 Why?
Cellulitis
1
2009
53
0.300
 Why?
Tomography, X-Ray Computed
7
2023
2738
0.300
 Why?
Antineoplastic Agents
6
2025
2197
0.290
 Why?
Carcinoma, Squamous Cell
1
2014
642
0.290
 Why?
Kaplan-Meier Estimate
7
2020
966
0.280
 Why?
Lymphocytes
3
2020
382
0.280
 Why?
Lymphoma, Mantle-Cell
2
2019
32
0.270
 Why?
Organ Sparing Treatments
2
2026
38
0.260
 Why?
Coronary Artery Disease
2
2026
741
0.260
 Why?
Consensus
3
2024
489
0.250
 Why?
Survival Analysis
6
2020
1385
0.240
 Why?
Cardiotoxicity
2
2023
33
0.240
 Why?
Lung Neoplasms
3
2026
2642
0.240
 Why?
Pregnancy Complications, Neoplastic
2
2017
63
0.240
 Why?
Testicular Neoplasms
2
2018
113
0.240
 Why?
Credentialing
1
2026
21
0.230
 Why?
Multiple Myeloma
2
2020
304
0.230
 Why?
Patient Selection
2
2022
719
0.230
 Why?
Radiation Pneumonitis
2
2016
31
0.230
 Why?
Pelvic Neoplasms
1
2025
24
0.230
 Why?
Heart
3
2018
636
0.220
 Why?
Urinary Tract
1
2025
49
0.220
 Why?
Urodynamics
1
2025
47
0.220
 Why?
Lymph Node Excision
2
2019
173
0.220
 Why?
Antimetabolites, Antineoplastic
2
2017
105
0.220
 Why?
Risk Factors
6
2026
10792
0.220
 Why?
Risk Assessment
6
2023
3676
0.220
 Why?
Leukemia
2
2017
245
0.210
 Why?
United States
5
2026
15988
0.210
 Why?
Lower Urinary Tract Symptoms
1
2025
59
0.210
 Why?
Transplantation, Haploidentical
1
2024
23
0.210
 Why?
Radiation Oncology
1
2025
89
0.210
 Why?
Central Nervous System
3
2021
281
0.200
 Why?
Magnetic Resonance Imaging
4
2019
3869
0.200
 Why?
Uterus
1
2025
226
0.200
 Why?
Quality Assurance, Health Care
1
2025
340
0.200
 Why?
Virtual Reality
1
2025
77
0.200
 Why?
Lymphadenopathy
1
2023
8
0.200
 Why?
Lymphatic Metastasis
3
2014
334
0.200
 Why?
Cord Blood Stem Cell Transplantation
1
2024
103
0.200
 Why?
Transplantation Conditioning
1
2024
186
0.190
 Why?
Comprehension
1
2025
180
0.190
 Why?
Neoplasm Grading
4
2019
309
0.190
 Why?
Remission Induction
3
2018
308
0.190
 Why?
Protons
2
2020
95
0.180
 Why?
Brain Stem Neoplasms
1
2023
87
0.180
 Why?
Bone Neoplasms
1
2024
256
0.180
 Why?
Gastric Mucosa
2
2019
52
0.180
 Why?
Radiometry
2
2019
57
0.180
 Why?
Mitogen-Activated Protein Kinase 7
1
2021
16
0.180
 Why?
Chemotherapy, Adjuvant
2
2013
421
0.180
 Why?
Cohort Studies
6
2024
5965
0.180
 Why?
Transplantation, Autologous
3
2018
292
0.170
 Why?
Survivors
2
2023
520
0.170
 Why?
Multimodal Imaging
3
2017
129
0.170
 Why?
Postoperative Complications
1
2014
2920
0.170
 Why?
Poly(ADP-ribose) Polymerases
1
2021
86
0.170
 Why?
Radium
1
2020
4
0.170
 Why?
Imaging, Three-Dimensional
1
2025
583
0.170
 Why?
Artificial Intelligence
1
2025
367
0.170
 Why?
Breath Holding
2
2017
10
0.170
 Why?
Long Term Adverse Effects
1
2020
13
0.160
 Why?
Cranial Irradiation
2
2023
85
0.160
 Why?
Patient Education as Topic
1
2025
780
0.150
 Why?
Skin Neoplasms
2
2018
847
0.150
 Why?
Stem Cell Transplantation
2
2018
191
0.150
 Why?
Plasmacytoma
1
2019
19
0.150
 Why?
Cardiology
1
2022
353
0.150
 Why?
Postoperative Care
2
2019
288
0.150
 Why?
CD4-CD8 Ratio
1
2018
23
0.150
 Why?
Radiation Dosage
1
2020
193
0.140
 Why?
Mycosis Fungoides
1
2018
62
0.140
 Why?
Methotrexate
2
2017
240
0.140
 Why?
Electrons
1
2018
88
0.140
 Why?
Breast Neoplasms, Male
1
2018
29
0.140
 Why?
Glioma
1
2023
426
0.140
 Why?
Area Under Curve
1
2019
331
0.140
 Why?
Peritoneal Neoplasms
1
2019
103
0.140
 Why?
Radiotherapy Setup Errors
1
2017
3
0.130
 Why?
Platelet Count
1
2017
96
0.130
 Why?
Autografts
1
2018
55
0.130
 Why?
Hypothyroidism
1
2018
67
0.130
 Why?
Craniospinal Irradiation
1
2017
5
0.130
 Why?
Dendritic Cell Sarcoma, Follicular
1
2017
4
0.130
 Why?
Eye Neoplasms
1
2017
30
0.130
 Why?
Leukocyte Count
1
2017
316
0.130
 Why?
Vincristine
4
2019
140
0.130
 Why?
Osteogenesis Imperfecta
2
2007
14
0.130
 Why?
Spinal Cord Diseases
1
2017
41
0.120
 Why?
Uncertainty
1
2017
145
0.120
 Why?
Pentostatin
1
2016
4
0.120
 Why?
Neoplasm, Residual
1
2017
139
0.120
 Why?
Photopheresis
1
2016
9
0.120
 Why?
Axilla
2
2017
51
0.120
 Why?
Methylprednisolone
1
2016
64
0.120
 Why?
Predictive Value of Tests
3
2022
2118
0.120
 Why?
Prospective Studies
5
2025
7997
0.120
 Why?
Plasmablastic Lymphoma
1
2015
8
0.120
 Why?
Confidence Intervals
1
2016
333
0.120
 Why?
Collagen Type I
2
2007
147
0.120
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2016
122
0.120
 Why?
Caregivers
2
2025
1049
0.120
 Why?
Fatal Outcome
1
2016
307
0.110
 Why?
Abortion, Spontaneous
1
2016
115
0.110
 Why?
Congenital Abnormalities
1
2016
104
0.110
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.110
 Why?
Hysterectomy
2
2013
138
0.110
 Why?
Anxiety
1
2023
1110
0.110
 Why?
Tacrolimus
1
2016
196
0.110
 Why?
Transplantation, Homologous
1
2016
415
0.110
 Why?
Proportional Hazards Models
4
2020
1325
0.110
 Why?
Drug Resistance, Neoplasm
2
2019
883
0.110
 Why?
Blood Platelets
1
2017
400
0.100
 Why?
Biomarkers
4
2021
4275
0.100
 Why?
Risk
1
2016
911
0.100
 Why?
Etoposide
3
2018
167
0.100
 Why?
Age Factors
1
2021
3335
0.100
 Why?
Receptors, Progesterone
2
2014
356
0.100
 Why?
Cyclophosphamide
3
2019
266
0.100
 Why?
Kidney Neoplasms
1
2018
412
0.100
 Why?
Rituximab
3
2019
210
0.100
 Why?
Carboplatin
1
2013
160
0.100
 Why?
Spinal Cord
1
2015
382
0.090
 Why?
Anti-Inflammatory Agents
1
2016
475
0.090
 Why?
Receptors, Estrogen
2
2014
457
0.090
 Why?
Fluorouracil
1
2013
235
0.090
 Why?
Lung
2
2016
4109
0.090
 Why?
Pelvis
1
2013
124
0.090
 Why?
Carcinoma, Non-Small-Cell Lung
1
2021
1182
0.090
 Why?
Paclitaxel
1
2013
256
0.090
 Why?
Immunoenzyme Techniques
1
2012
200
0.090
 Why?
Immunohistochemistry
1
2016
1718
0.090
 Why?
Neutrophils
1
2017
1134
0.090
 Why?
Health Knowledge, Attitudes, Practice
1
2020
1416
0.090
 Why?
Immunosuppressive Agents
1
2016
847
0.090
 Why?
Cisplatin
1
2013
334
0.080
 Why?
Triple Negative Breast Neoplasms
1
2014
216
0.080
 Why?
Brain
2
2020
2941
0.080
 Why?
Immunotherapy
1
2015
657
0.080
 Why?
Models, Biological
1
2018
1822
0.080
 Why?
Contrast Media
1
2013
488
0.080
 Why?
Polymorphism, Single Nucleotide
1
2016
2147
0.070
 Why?
Patient Compliance
1
2013
589
0.070
 Why?
Dose-Response Relationship, Radiation
2
2020
140
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
2
2019
97
0.070
 Why?
Liver Neoplasms
1
2014
783
0.070
 Why?
Prednisone
2
2019
221
0.060
 Why?
Cytarabine
2
2018
66
0.060
 Why?
Biomarkers, Tumor
1
2014
1322
0.060
 Why?
Integrins
1
2007
90
0.060
 Why?
Proteoglycans
1
2007
110
0.060
 Why?
Practice Guidelines as Topic
1
2014
1563
0.060
 Why?
Colorectal Neoplasms
1
2014
848
0.060
 Why?
Time Factors
4
2018
7183
0.060
 Why?
Treatment Failure
2
2018
365
0.060
 Why?
Amino Acid Substitution
1
2006
304
0.060
 Why?
Glycine
1
2006
187
0.060
 Why?
Neoplasm Invasiveness
2
2017
509
0.050
 Why?
Fertility Preservation
1
2025
53
0.050
 Why?
Clinical Decision-Making
2
2019
359
0.050
 Why?
American Heart Association
1
2026
350
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2023
13
0.050
 Why?
Intelligence Tests
1
2023
56
0.050
 Why?
Standard of Care
1
2024
80
0.050
 Why?
X-Rays
1
2023
31
0.050
 Why?
Cell- and Tissue-Based Therapy
1
2024
80
0.050
 Why?
Regression Analysis
2
2016
1003
0.050
 Why?
Proto-Oncogene Proteins c-sis
1
2023
39
0.050
 Why?
Analysis of Variance
2
2016
1311
0.050
 Why?
Pregnancy
3
2025
7191
0.050
 Why?
Inducible T-Cell Co-Stimulator Protein
1
2022
10
0.050
 Why?
Cytidine Deaminase
1
2023
59
0.050
 Why?
Phenotype
3
2021
3164
0.050
 Why?
Terminology as Topic
1
2024
255
0.050
 Why?
Brain Stem
1
2023
96
0.050
 Why?
Ribose
1
2021
22
0.040
 Why?
Adenosine Diphosphate
1
2021
84
0.040
 Why?
Troponin T
1
2021
65
0.040
 Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
53
0.040
 Why?
Feedback
1
2021
181
0.040
 Why?
Radiosurgery
1
2024
401
0.040
 Why?
Immunotherapy, Adoptive
1
2024
337
0.040
 Why?
Automation
1
2020
102
0.040
 Why?
Risk Management
1
2020
84
0.040
 Why?
Prevalence
2
2016
2836
0.040
 Why?
Incidence
2
2016
2883
0.040
 Why?
Mesentery
1
2019
45
0.040
 Why?
Infant
2
2025
10039
0.040
 Why?
Workflow
1
2020
185
0.040
 Why?
Neuropsychological Tests
1
2023
1137
0.040
 Why?
Busulfan
1
2018
16
0.030
 Why?
Respiration
1
2019
207
0.030
 Why?
Melphalan
1
2018
43
0.030
 Why?
Safety
1
2020
356
0.030
 Why?
Carmustine
1
2018
52
0.030
 Why?
Algorithms
1
2025
1839
0.030
 Why?
Cone-Beam Computed Tomography
1
2017
30
0.030
 Why?
Inhalation
1
2017
29
0.030
 Why?
Breast
1
2018
159
0.030
 Why?
Subacute Combined Degeneration
1
2017
1
0.030
 Why?
Phosphorylation
1
2021
1733
0.030
 Why?
Photons
1
2017
76
0.030
 Why?
Injections, Spinal
1
2017
121
0.030
 Why?
Deoxycytidine
1
2018
221
0.030
 Why?
Orbit
1
2017
64
0.030
 Why?
New York
1
2016
127
0.030
 Why?
Time-to-Treatment
1
2019
245
0.030
 Why?
Lymph Nodes
1
2019
502
0.030
 Why?
Homocysteine
1
2017
151
0.030
 Why?
Procarbazine
1
2015
9
0.030
 Why?
Genetic Markers
1
2016
331
0.030
 Why?
Observer Variation
1
2016
355
0.030
 Why?
Transforming Growth Factor beta1
1
2016
178
0.030
 Why?
Mutation
1
2007
4099
0.030
 Why?
Folic Acid
1
2017
199
0.030
 Why?
Texas
1
2016
278
0.030
 Why?
Animals
2
2021
38109
0.030
 Why?
Molecular Targeted Therapy
1
2018
434
0.030
 Why?
Mitochondria
1
2021
984
0.030
 Why?
Gastrointestinal Diseases
1
2016
216
0.030
 Why?
Secondary Prevention
1
2016
255
0.030
 Why?
Diagnostic Imaging
1
2017
339
0.030
 Why?
Abortion, Induced
1
2016
110
0.030
 Why?
Drug Administration Schedule
1
2016
783
0.030
 Why?
Pregnancy Outcome
1
2017
476
0.030
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
293
0.030
 Why?
Acute Disease
1
2016
1031
0.030
 Why?
Postpartum Period
1
2016
365
0.020
 Why?
Mastectomy
1
2014
162
0.020
 Why?
Multivariate Analysis
1
2016
1540
0.020
 Why?
Diagnosis, Differential
1
2017
1495
0.020
 Why?
CD8-Positive T-Lymphocytes
1
2018
917
0.020
 Why?
Ultrasonography
1
2016
770
0.020
 Why?
CD4-Positive T-Lymphocytes
1
2018
1129
0.020
 Why?
Surveys and Questionnaires
1
2025
6053
0.020
 Why?
Ovariectomy
1
2012
162
0.020
 Why?
Medical Oncology
1
2014
332
0.020
 Why?
Comorbidity
1
2016
1660
0.020
 Why?
Severity of Illness Index
1
2019
2925
0.020
 Why?
Diet
1
2017
1275
0.020
 Why?
Kidney
1
2017
1496
0.020
 Why?
Quality of Life
1
2021
3192
0.020
 Why?
Electronic Health Records
1
2017
1177
0.020
 Why?
Reproducibility of Results
1
2016
3415
0.020
 Why?
Anti-Bacterial Agents
1
2019
1915
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2365
0.020
 Why?
Electrophoresis
1
2006
31
0.020
 Why?
Case-Control Studies
1
2014
3608
0.010
 Why?
DNA Mutational Analysis
1
2007
409
0.010
 Why?
Databases, Genetic
1
2007
249
0.010
 Why?
Protein Structure, Tertiary
1
2007
862
0.010
 Why?
Collagen
1
2007
456
0.010
 Why?
Mice
1
2021
18365
0.010
 Why?
Binding Sites
1
2007
1331
0.010
 Why?
Protein Binding
1
2007
2276
0.010
 Why?
Cells, Cultured
1
2006
4155
0.010
 Why?
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (363) concept(s)
_
Co-Authors Expand Description
See all (39) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)